# Vivo Capital

> Vivo Capital is a VC fund in Palo Alto backing Biotechnology and Health Care. See 253 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Palo Alto, United States
- Total investments: 253
- Last investment: Aug 2026
- Lead investor: 26%
- Fund size: $1.4B
- Last fund: Oct 2019
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/vivo-capital
- Website: http://vivocapital.com/

Vivo Capital is a VC fund in Palo Alto focused on Biotechnology and Health Care. The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists,entrepreneurs, operating executives, and industry experts. The firm operates as a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.

## Contacts

5 contacts available for Vivo Capital. Shizune tracks 12 team members at Vivo Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/vivo-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $28M–$125M |
| Series C | $30M–$108M |
| Post-IPO Equity | $40M–$180M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 118 | 47% |
| Health Care | 86 | 34% |
| Pharmaceutical | 58 | 23% |
| Medical | 52 | 21% |
| Therapeutics | 48 | 19% |

49 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 39 | 15% |
| Series B | 37 | 15% |
| Series C | 37 | 15% |
| Series A | 35 | 14% |
| Series D | 15 | 6% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 107 | 42% |
| China | 20 | 8% |
| United Kingdom | 6 | 2% |
| Canada | 5 | 2% |
| Singapore | 2 | 1% |

12 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Gaurav Aggarwal | Managing Director | 6 | https://shizune.co/investors/profile/gaurav-aggarwal |
| Mahendra G. Shah | Managing Director | 2 | https://shizune.co/investors/profile/mahendra-g-shah |
| Michael Chang | Managing Partner | 0 | https://shizune.co/investors/profile/michael-chang-2 |
| Shan Fu | Managing Partner, Co-CEO, and CEO of Asia Pacific | 5 | https://shizune.co/investors/profile/shan-fu |
| Chloe Zhang | Principal | 0 | https://shizune.co/investors/profile/chloe-zhang-1 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Expedition Therapeutics | Expedition Therapeutics operates as an unincorporated association. | $115M | Series B | Aug 05, 2026 |  |
| Entera Bio | Entera Bio is developing novel oral drugs by utilizing its proprietary cutting edge delivery technology This technology protects large molecules and peptides in the GI tract. Oral drug delivery is the most straight forward and user friendly approach to medical treatment. Entera Bio has key personnel with the relevant know how, experience andnetworks working together to enable rapid development of its products. The company has an experienced management team with more than 50 years of combined drug development experience. | $275M | Post-IPO Equity | Jul 27, 2026 |  |
| Mentari Therapeutics | Mentari Therapeutics is a biotechnology company developing therapies for the prevention of migraine. | $200M | Private Equity | Jul 22, 2026 |  |
| SonoThera | SonoThera is a biotechnology company that creates non-viral genetic therapies using ultrasound. Its mission is to develop genetic medicines that treat the root cause of human disease. SonoThera is expanding the possibilities of disease treatment with ultrasound-guided nonviral gene therapy for diseases with suboptimal or non-existent treatments. Itaims to improve the lives and health of millions of people. | $125M | Series B | Jun 10, 2026 |  |
| Full-Life Technologies | Full-Life Technologies Limited (“Full-Life”) is a fully integrated global RadioTherapeutics company headquartered in Shanghai, China with operations in Europe. | $109M | Series D | May 18, 2026 |  |
| Immunocan | Immunocan focuses on the development of fully human antibody animals, artificial chromosome carriers with independent intellectual property rights, focusing on tumor treatment, and developing antibody therapeutic drugs. | $36.8M | Series A | May 13, 2026 |  |
| Valneva | Valneva is a pharmaceutical company developing prophylactic vaccines to treat infectious diseases. The company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. Valneva has leveraged its expertise and capabilities both to commercialize two vaccines successfully and torapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus, and COVID-19. | $43.1M | Post-IPO Equity | Apr 30, 2026 |  |
| Achieve Life Science | Achieve Life Science manufactures pharmaceutical products. The firm develops cytisine as a smoking cessation aid. | $180M | Post-IPO Equity | Apr 16, 2026 |  |
| Oricell Therapeutics | OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy. | $110M | Venture - Series Unknown | Apr 09, 2026 |  |
| OnKure Therapeutics | OnKure is a biotechnology company that commercializes a new cancer therapy based on novel, less toxic kinase inhibitor drugs. The company is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that includes selective inhibitors of histone deacetylases. In pre-clinical models of both hematological and solidtumor cancers, their lead candidate, OKI-179, significantly and safely reduces the growth rate of tumors when dosed by itself or in combination with other targeted therapies.OnKure advances the HDAC3 selective inhibitor OKI-422 into pre-clinical toxicology studies. The company's drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized. | $150M | Post-IPO Equity | Mar 27, 2026 |  |

10 of 253 investments shown.

## Co-investors
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 45 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 38 deals together
- [Logos Capital](https://shizune.co/investors/profile/logos-capital) — VC Fund, 37 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 26 deals together
- [venBio Partners](https://shizune.co/investors/profile/venbio) — VC Fund, 26 deals together
- [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures) — VC Fund, 21 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## Featured in investor lists
- [Biotech Investors in United States](https://shizune.co/investors/biotech-investors-united-states)
- [Biotech VC Funds in United States](https://shizune.co/investors/biotech-vc-funds-united-states)
- [Life Science Investors](https://shizune.co/investors/life-science-investors)
- [Life Science VC Funds](https://shizune.co/investors/life-science-vc-funds)
- [Life Science Investors in United States](https://shizune.co/investors/life-science-investors-united-states)
- [Life Science VC Funds in United States](https://shizune.co/investors/life-science-vc-funds-united-states)

## FAQ

### What does Vivo Capital invest in?

Vivo Capital invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Post-IPO Equity and Series B stage. Most of the 253 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Vivo Capital's check size?

Vivo Capital typically joins rounds of $28M–$125M at Series B, $30M–$108M at Series C and $40M–$180M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Vivo Capital participates in.

### How do I contact Vivo Capital?

Public channels for Vivo Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Vivo Capital?

The team at Vivo Capital includes Gaurav Aggarwal (Managing Director), Mahendra G. Shah (Managing Director) and Michael Chang (Managing Partner), among 12 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co